← Back to Clinical Trials
Recruiting Phase 1 NCT07334080

ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants

Trial Parameters

Condition Metabolic Dysfunction-Associated Steatohepatitis
Sponsor Eccogene
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 72
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2026-01-10
Completion 2026-05
Interventions
ECC4703 F0 formulationECC4703 F1 formulationECC4703 F2 formulation

Brief Summary

This is a Phase I, open-label, randomized, single-dose, 2-part study designed to evaluate the food effect and relative bioavailability of ECC4703 in healthy adult participants.

Eligibility Criteria

Inclusion Criteria: * Healthy male and female participants * Age of 18 to 65 years * BMI of 18.0 to 32.0 kg/m2 with a minimum body weight of 50.0 kg (110 lb) for males and 45.0 kg (99 lb) for females. * Female participants of childbearing potential must have negative serum pregnancy test at screening and a negative serum or urine pregnancy test prior to the first dose of study drug; use at least 1 highly effective method of contraception (e.g., hormonal contraception, intrauterine device, bilateral tubal occlusion, or vasectomized partner with confirmed success) during the study and for at least 90 days after the last dose of study drug; and refrain from egg donation or fertility treatments during the same period. * Female participants who are postmenopausal, confirmed by FSH test, or surgically sterile, confirmed by medical documentation, or agree to practice true abstinence * Male participants agree to use contraception, or agree to practice true abstinence * Not taking any medicatio

Related Trials